Top

Current Hematologic Malignancy Reports

Published in:

01-02-2018 | T-Cell and Other Lymphoproliferative Malignancies (J Zain, Section Editor)

NK/T Cell Lymphoma: Updates in Therapy

Author: Ritsuro Suzuki

Published in: Current Hematologic Malignancy Reports | Issue 1/2018

Abstract

Purpose of Review

Extranodal NK/T cell lymphoma (ENKL), nasal type, is a highly aggressive lymphoma which used to show a poor clinical outcome. Expression of P-glycoprotein on lymphoma cells of ENKL is a major reason for the refractoriness to conventional chemotherapy containing anthracycline. However, recent innovative approaches have improved the outcome and prognosis of ENKL. The purpose of this review is to summarize the proceedings of treatment.

Recent Findings

Concurrent chemoradiotherapy containing platinum and several drugs including L-asparaginase, methotrexate, and alkylators shows excellent outcomes for the limited-stage ENKL. SMILE (steroid, methotrexate, ifosfamide, L-asparaginase, and etoposide) or other L-asparaginase-containing therapy is promising for advanced-stage ENKL, followed by either autologous or allogeneic hematopoietic stem cell transplantation. Anti-PD-1 or other immunological checkpoint inhibitors are recently reported to be effective for relapsed/refractory ENKL thought to be due to EBV-driven upregulation of PD-L1 expression.

Summary

The prognosis of ENKL is therefore improving by the introduction of these strategies. The 5-year overall survival (OS) rate of limited stage was 63.2% [95% confidence interval (CI), 55.3 to 70.0%] before 2010, but was 79.4% (95% CI, 66.9 to 87.6%) in 2010 or after. However, there still exists a room for improvement, particularly for advanced-stage patients. The 2-year OS of advanced ENKL was 30.3% (95% CI, 19.5 to 41.7%) before 2010, but was 40.5% (95% CI, 24.8 to 55.8%) in 2010 or after. Optimal treatment scheme should further be explored.

Chan JKC, Quintanilla-Martinez L, Ferry JA. Extranodal NK/T-cell lymphoma, nasal type. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of Tumours of Haematopoietic and lymphoid tissues. Lyon, France: IARC; 2017. p. 368–71.

Suzuki R, Suzumiya J, Yamaguchi M, Nakamura S, Kameoka J, Kojima H, et al. Prognostic factors for mature natural killer (NK)-cell neoplasms: aggressive NK-cell leukemia and extranodal NK-cell lymphoma, nasal-type. Ann Oncol. 2010;21(5):1032–40. https://doi.org/10.1093/annonc/mdp418.CrossRefPubMed

Kim SJ, Yoon DH, Jaccard A, Chng WJ, Lim ST, Hong H, et al. A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis. Lancet Oncol. 2016;17(3):389–400. https://doi.org/10.1016/S1470-2045(15)00533-1.CrossRefPubMed

Cheung MMC, Chan JKC, Lau WH, et al. Primary non-Hodgkin's lymphoma of the nose and nasopharynx: clinical features, tumor immunophenotype, and treatment outcome in 113 patients. J Clin Oncol. 1998;16(1):70–7. https://doi.org/10.1200/JCO.1998.16.1.70.CrossRefPubMed

Kim GE, Koom WS, Yang WI, Lee SW, Keum KC, Lee CG, et al. Clinical relevance of three subtypes of primary sinonasal lymphoma characterized by immunophenotypic analysis. Head Neck. 2004;26(7):584–93. https://doi.org/10.1002/hed.20015.CrossRefPubMed

Pongpruttipan T, Sukpanichnant S, Assanasen T, Wannakrairot P, Boonsakan P, Kanoksil W, et al. Extranodal NK/T-cell lymphoma, nasal type, includes cases of natural killer cell and αβ, γδ, and αβ/γδ T-cell origin: a comprehensive clinicopathologic and phenotypic study. Am J Surg Pathol. 2012;36(4):481–99. https://doi.org/10.1097/PAS.0b013e31824433d8.CrossRefPubMed

Sakajiri S, Kawamata N, Egashira M, Mori K, Oshimi K. Molecular analysis of tumor suppressor genes, Rb, p53, p16INK4A, p15INK4B and p14ARF in natural killer cell neoplasms. Jpn J Cancer Res. 2001;92(10):1048–56. https://doi.org/10.1111/j.1349-7006.2001.tb01059.x.CrossRefPubMed

Nakashima Y, Tagawa H, Suzuki R, Karnan S, Karube K, Ohshima K, et al. Genome-wide array-based comparative genomic hybridization of natural killer cell lymphoma/leukemia: different genomic alteration patterns of aggressive NK-cell leukemia and extranodal NK/T-cell lymphoma, nasal type. Genes Chromosomes Cancer. 2005;44(3):247–55. https://doi.org/10.1002/gcc.20245.CrossRefPubMed

Berti E, Recalcati S, Girgenti V, Fanoni D, Venegoni L, Vezzoli P. Cutaneous extranodal NK/T-cell lymphoma: a clinicopathologic study of 5 patients with array-based comparative genomic hybridization. Blood. 2010;116(2):165–70. https://doi.org/10.1182/blood-2009-11-252957.CrossRefPubMed

10.

Ahn HK, Suh C, Chuang SS, Suzumiya J, Ko YH, Kim SJ, et al. Extranodal natural killer/T cell lymphoma from skin or soft tissue: suggestion of treatment from multinational retrospective analysis. Ann Oncol. 2012;23(10):2703–7. https://doi.org/10.1093/annonc/mds096.CrossRefPubMed

11.

Kim SJ, Jung HA, Chuang SS, Hong H, Guo CC, Cao J, et al. Extranodal natural killer/T-cell lymphoma involving the gastrointestinal tract: analysis of clinical features and outcomes from the Asia lymphoma study group. J Hematol Oncol. 2013;6(1):86. https://doi.org/10.1186/1756-8722-6-86.CrossRefPubMedPubMedCentral

12.

Suzuki R, Suzumiya J, Oshimi K. Differences between nasal and extra-nasal NK/T-cell lymphoma. Blood. 2009;113(24):6260–1. https://doi.org/10.1182/blood-2009-03-211011.CrossRefPubMed

13.

Egashira M, Kawamata N, Sugimoto K, Kaneko T, Oshimi K. P-glycoprotein expression on normal and abnormally expanded natural killer cells and inhibition of P-glycoprotein function by cyclosporin A and its analogue, PSC833. Blood. 1999;93(2):599–606.PubMed

14.

Kim WS, Song SY, Ahn YC, Ko YH, Baek CH, Kim DY, et al. CHOP followed by involved field radiation: is it optimal for localized nasal natural killer/T-cell lymphoma? Ann Oncol. 2001;12(3):349–52. https://doi.org/10.1023/A:1011144911781.CrossRefPubMed

15.

Kim SJ, Kim BS, Choi CW, Seo HY, Seol HR, Sung HJ, et al. Treatment outcome of front-line systemic chemotherapy for localized extranodal NK/T cell lymphoma in nasal and upper aerodigestive tract. Leuk Lymphoma. 2006;47(7):1265–73. https://doi.org/10.1080/10428190600565651.CrossRefPubMed

16.

Li YX, Coucke PA, Li JY, Gu DZ, Liu XF, Zhou LQ, et al. Primary non-Hodgkin's lymphoma of the nasal cavity: prognostic significance of paranasal extension and the role of radiotherapy and chemotherapy. Cancer. 1998;83(3):449, 1998–56. https://doi.org/10.1002/(SICI)1097-0142(19980801)83:3<449::AID-CNCR13>3.0.CO;2-W.CrossRefPubMed

17.

Li YX, Yao B, Jin J, Wang WH, Liu YP, Song YW, et al. Radiotherapy as primary treatment for stage IE and IIE nasal natural killer/T-cell lymphoma. J Clin Oncol. 2006;24(1):181–9. https://doi.org/10.1200/JCO.2005.03.2573.CrossRefPubMed

18.

You JY, Chi KH, Yang MH, Chen CC, Ho CH, Chau WK, et al. Radiation therapy versus chemotherapy as initial treatment for localized nasal natural killer (NK)/T-cell lymphoma: a single institute survey in Taiwan. Ann Oncol. 2004;15(4):618–25. https://doi.org/10.1093/annonc/mdh143.CrossRefPubMed

19.

Yamaguchi M, Tobinai K, Oguchi M, Ishizuka N, Kobayashi Y, Isobe Y, et al. Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan clinical oncology group study JCOG0211. J Clin Oncol. 2009;27(33):5594–600. https://doi.org/10.1200/JCO.2009.23.8295.CrossRefPubMed

20.

Kim SJ, Kim K, Kim BS, Kim CY, Suh C, Huh J, et al. Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-cell lymphoma: consortium for improving survival of lymphoma study. J Clin Oncol. 2009;27(35):6027–32. https://doi.org/10.1200/JCO.2009.23.8592.CrossRefPubMed

21.

Kim SJ, Yang DH, Kim JS, Kwak JY, Eom HS, Hong DS, et al. Concurrent chemoradiotherapy followed by L-asparaginase-containing chemotherapy, VIDL, for localized nasal extranodal NK/T cell lymphoma: CISL08-01 phase II study. Ann Hematol. 2014;93(11):1895–901. https://doi.org/10.1007/s00277-014-2137-6.CrossRefPubMed

22.

Yamaguchi M, Tobinai K, Oguchi M, Ishizuka N, Kobayashi Y, Isobe Y, et al. Concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: an updated analysis of the Japan clinical oncology group study JCOG0211. J Clin Oncol. 2012;30(32):4044–6. https://doi.org/10.1200/JCO.2012.45.6541.CrossRefPubMed

23.

•• Yamaguchi M, Suzuki R, Oguchi M, Asano N, Amaki J, Akiba T, et al. Treatments and outcomes of patients with extranodal natural killer/T-cell lymphoma who were diagnosed between 2000 and 2013: a cooperative study in Japan. J Clin Oncol. 2017;35(1):32–9. The NKEA study showed that prognosis of limited-stage ENKL has improved in the daily practice. https://doi.org/10.1200/JCO.2016.68.1619.CrossRefPubMed

24.

Kwong YL, Kim WS, Lim ST, Kim SJ, Tang T, Tse E, et al. SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia lymphoma study group. Blood. 2012;120(15):2973–80. https://doi.org/10.1182/blood-2012-05-431460.CrossRefPubMed

25.

Kwong YL, Kim SJ, Tse E, et al. Sequential chemotherapy/radiotherapy was comparable with concurrent chemoradiotherapy for stage I/II NK/T-cell lymphoma. Ann Oncol. 2017.

26.

Nagafuji K, Fujisaki T, Arima F, Ohshima K. L-asparaginase induced durable remission of relapsed nasal NK/T-cell lymphoma after autologous peripheral blood stem cell transplantation. Int J Hematol. 2001;74(4):447–50. https://doi.org/10.1007/BF02982090.CrossRefPubMed

27.

Obama K, Tara M, Niina K. L-asparaginase-based induction therapy for advanced extranodal NK/T-cell lymphoma. Int J Hematol. 2003;78(3):248–50. https://doi.org/10.1007/BF02983802.CrossRefPubMed

28.

Matsumoto Y, Nomura K, Kanda-Akano Y, Fujita Y, Nakao M, Ueda K, et al. Successful treatment with Erwinia L-asparaginase for recurrent natural killer/T cell lymphoma. Leuk Lymphoma. 2003;44(5):879–82. https://doi.org/10.1080/1042819031000067873.CrossRefPubMed

29.

Ando M, Sugimoto K, Kitoh T, Sasaki M, Mukai K, Ando J, et al. Selective apoptosis of natural killer-cell tumours by l-asparaginase. Br J Haematol. 2005;130(6):860–8. https://doi.org/10.1111/j.1365-2141.2005.05694.x.CrossRefPubMed

30.

Suzuki R. Treatment of advanced extranodal NK/T cell lymphoma, nasal-type and aggressive NK-cell leukemia. Int J Hematol. 2010;92(5):697–701. https://doi.org/10.1007/s12185-010-0726-2.CrossRefPubMed

31.

Yamaguchi M, Kwong YL, Kim WS, Maeda Y, Hashimoto C, Suh C, et al. Phase II study of SMILE chemotherapy for newly-diagnosed stage IV, relapsed or refractory extranodal NK/T-cell lymphoma, nasal type: the NK-cell tumor study group (NKTSG) study. J Clin Oncol. 2011;29(33):4410–6. https://doi.org/10.1200/JCO.2011.35.6287.CrossRefPubMed

32.

Suzuki R, Kwong Y, Maeda Y, et al. 5-year follow-up of the SMILE phase II study for newly diagnosed stage IV, relapsed or refractory extranodal NK/T-cell lymphoma, nasal type. Hematol Oncol. 2015;33(Supple. S1):140. [Abstract #075]

33.

Jaccard A, Gachard N, Marin B, Rogez S, Audrain M, Suarez F, et al. Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase II study. Blood. 2011;117(6):1834–9. https://doi.org/10.1182/blood-2010-09-307454.CrossRefPubMed

34.

Jaccard A, Suerez F, Delmer A, et al. A prospective phase II trial of an L-asparaginase containing regimen in extranodal NK/T-cell lymphoma. Hematol Oncol. 2013;31(Supple. S1):129. [Abstract #099]

35.

Suzuki R. Leukemia and lymphoma of natural killer cells. J Clin Exp Hematop. 2005;45(2):51–70. https://doi.org/10.3960/jslrt.45.51.CrossRef

36.

Au WY, Lie AK, Liang R, Kwong YL, Yau CC, Cheung MM, et al. Autologous stem cell transplantation for nasal NK/T-cell lymphoma: a progress report on its value. Ann Oncol. 2003;14(11):1673–6. https://doi.org/10.1093/annonc/mdg458.CrossRefPubMed

37.

Suzuki R, Suzumiya J, Nakamura S, et al. Hematopoietic stem cell transplantation for natural killer-cell lineage neoplasms. Bone Marrow Transplant. 2006;37(4):425–31. https://doi.org/10.1038/sj.bmt.1705244.CrossRefPubMed

38.

Kim HJ, Bang SM, Lee J, Kwon HC, Suh C, Kim HJ, et al. High-dose chemotherapy with autologous stem cell transplantation in extranodal NK/T-cell lymphoma: a retrospective comparison with non-transplantation cases. Bone Marrow Transplant. 2006;37(9):819–24. https://doi.org/10.1038/sj.bmt.1705349.CrossRefPubMed

39.

Yhim HY, Kim JS, Mun YC, Moon JH, Chae YS, Park Y, et al. Clinical outcomes and prognostic factors of up-front autologous stem cell transplantation in patients with extranodal natural killer/T cell lymphoma. Biol Blood Marrow Transplant. 2015;21(9):1597–604. https://doi.org/10.1016/j.bbmt.2015.05.003.CrossRefPubMed

40.

Lee J, Au WY, Park MJ, Suzumiya J, Nakamura S, Kameoka JI, et al. Autologous hematopoietic stem cell transplantation in extranodal NK/T-cell lymphoma: a multinational, multicenter, matched controlled study. Biol Blood Marrow Transplant. 2008;14(12):1356–64. https://doi.org/10.1016/j.bbmt.2008.09.014.CrossRefPubMed

41.

• Kharfan-Dabaja MA, Kumar A, Ayala E, Hamadani M, Reimer P, Gisselbrecht C, et al. Clinical practice recommendations on indication and timing of hematopoietic cell transplantation in mature T-cell and NK/T-cell lymphomas: an international collaborative effort on behalf of the Guidelines Committee of the American Society for blood and marrow transplantation. Biol Blood Marrow Transplant. 2017;23(11):1826–38. The ASBMT recommendation summarized the opinion of lymphoma experts for the HSCT in ENKL. https://doi.org/10.1016/j.bbmt.2017.07.027.CrossRefPubMed

42.

Murashige N, Kami M, Kishi Y, Kim SW, Takeuchi M, Matsue K, et al. Allogeneic haematopoietic stem cell transplantation as a promising treatment for natural killer-cell neoplasms. Br J Haematol. 2005;130(4):561–7. https://doi.org/10.1111/j.1365-2141.2005.05651.x.CrossRefPubMed

43.

Kanate AS, DiGilio A, Ahn KW, et al. Allogeneic haematopoietic cell transplantation for extranodal natural killer/T-cell lymphoma, nasal type: a CIBMTR analysis. Br J Haematol. 2017.

44.

Suzuki R, Kako S, Hyo R, et al. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for extranodal NK/T-cell lymphoma, nasal-type: analysis of the Japan Society for Hematopoietic Cell Transplantation (JSHCT) lymphoma working group. Blood. 2011;118:503a. [Abstract #503]

45.

Buchbinder EI, Desai A. CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. Am J Clin Oncol. 2016;39(1):98–106. https://doi.org/10.1097/COC.0000000000000239.CrossRefPubMedPubMedCentral

46.

Green MR, Rodig S, Juszczynski P, Ouyang J, Sinha P, O'Donnell E, et al. Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy. Clin Cancer Res. 2012;18(6):1611–8. https://doi.org/10.1158/1078-0432.CCR-11-1942.CrossRefPubMedPubMedCentral

47.

Chen BJ, Chapuy B, Ouyang J, Sun HH, Roemer MGM, Xu ML, et al. PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clin Cancer Res. 2013;19(13):3462–73. https://doi.org/10.1158/1078-0432.CCR-13-0855.CrossRefPubMedPubMedCentral

48.

•• Kwong YL, Chan TSY, Tan D, Kim SJ, Poon LM, Mow B, et al. PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing L-asparaginase. Blood. 2017;129(17):2437–42. The checkpoint inhibitor antibody was dramatically effective for relapsed/refractory ENKL. https://doi.org/10.1182/blood-2016-12-756841.CrossRefPubMed

49.

Chan TSY, Li J, Loong F, Khong PL, Tse E, Kwong YL. PD1 blockade with low-dose nivolumab in NK/T cell lymphoma failing L-asparaginase: efficacy and safety. Ann Hematol. 2017.

Title: NK/T Cell Lymphoma: Updates in Therapy
Author: Ritsuro Suzuki
Publication date: 01-02-2018
Publisher: Springer US
Published in: Current Hematologic Malignancy Reports / Issue 1/2018
Print ISSN: 1558-8211
Electronic ISSN: 1558-822X
DOI: https://doi.org/10.1007/s11899-018-0430-5

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 1/2018

The Future of Combination Therapies for Peripheral T Cell Lymphoma (PTCL)

Central Nervous System Involvement in Peripheral T Cell Lymphoma

Biomarkers in Graft-Versus-Host Disease: from Prediction and Diagnosis to Insights into Complex Graft/Host Interactions

Rethinking Antimicrobial Prophylaxis in the Transplant Patient in the World of Emerging Resistant Organisms—Where Are We Today?

Immunologic Milieu of Mature T-Cell and NK-Cell Lymphomas—Implications for Therapy

Twitter Use in the Hematopoietic Cell Transplantation Community

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage